Observational Study on Patients With Hepatobiliary Tumors
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Evaluate the overall survival rate of all patients with hepatobiliary tumor
研究概览
简要总结
Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, the patient with hepatobiliary tumors even accepted radical surgery, the postoperative recurrence rate is still high. Therefore, it is of great significance to find important prognostic markers to improve patient prognosis and formulate new treatment plans. In recent years, targeted therapy and immunotherapy make cancer treatment enter a new field, However, tumor heterogeneity is the greatest challenge in cancer therapeutics and biomarkers discovery. In this study, we collected a wide rang of patients' information, including photos of patients' face, physical strength and nutrition indicators, blood ,stool and pathological tissue specimens from tumor patients, then Multi-omics testing were applied to Looking for novel therapeutic targets and prognostic markers to predict patient response to treatment. Clinicians choose the best treatment plan for the patient based on the test results to improve the patient's survival time and quality of life.
详细描述
This is an ongoing, longitudinal, observational clinical cohort study of patients with tumors of the alimentary tract, mainly hepatobiliary tumors. All the patients are diagnosed, treated and followed up. In the future, some other patient information will be gradually updated to this database
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be older than 18 years old;
- •Clinical or pathological diagnosis of malignant hepatobiliary tumors;
- •Patients have received or are about to receive surgery, chemotherapy radiotherapy, targeted therapy, local therapy, immunotherapy, etc;
- •Patients understand and are willing to sign written informed consent.
排除标准
- •Patients considered by the doctor to be unsuitable for entry into this study (mental disorder or poor compliance, etc.);
- •The patient or guardian is unwilling to participate in this study;
- •Pregnant women;
- •Combined with other serious systemic diseases (heart failure, renal failure,hematopoietic system disease or Uncontrollable acute infection);
- •Estimated survival time is less than 1 month.
结局指标
主要结局
Evaluate the overall survival rate of all patients with hepatobiliary tumor
时间窗: 5 years
In order to identify the potential influence factors of hepatobiliary tumor patients survival
次要结局
- Evaluate the recurrence free survival rate of patients with hepatobiliary tumor(5 years)
- Evaluate the Progression Free Survival rate of patients with hepatobiliary tumor(5 years)
- Evaluate the cancer-specific survival rate of patients with hepatobiliary tumor(5 years)
研究者
Gang Chen, MD
Division Chief of Education; Deputy Director of Hepatobiliary Surgery
First Affiliated Hospital of Wenzhou Medical University